Skip to main content
. 2019 Oct 26;15(1):127–134. doi: 10.1007/s11739-019-02214-0

Table 1.

Characteristics of the study participants by avoiding neuromuscular blocking agent

Total n = 411 Avoiding NMBA n = 46 Using NMBA n = 365 p value
Tracheostomy during the ICU stay, n (%) 61 (14.8) 16 (34.8) 45 (12.3) < 0.001
Adverse events during intubation, n (%) 98 (23.8) 8 (17.4) 90 (24.7) 0.18
 Esophageal intubation, n (%) 2 (0.5) 0 (0) 2 (0.6) 1.00
 Airway injury, n (%) 7 (1.7) 1 (2.2) 6 (1.6) 0.57
 Hypoxemia, n (%) 23 (5.6) 3 (6.5) 20 (5.5) 0.73
 Hypotension, n (%) 73 (17.8) 4 (8.7) 69 (18.9) 0.10
ICU mortality, n (%) 17 (4.1) 3 (6.5) 14 (3.8) 0.42
Hospital mortality, n (%) 74 (18.0) 12 (26.1) 62 (17.0) 0.15
Length of ICU stay (days), median (IQR) 6 (4–10) 7.5 (5–12) 6 (4–10) 0.09
Length of HP stay (days), median (IQR) 26 (14–42) 21 (11–42) 26 (15–42) 0.15
Ventilator days, median (IQR) 4 (2–7) 5 (3–9) 4 (2–7) 0.01
Sex (male), n (%) 259 (63.0) 27 (58.7) 232 (63.6) 0.52
Age (years), median (IQR) 70 (55–79) 74 (61–82) 69 (55–79) 0.12
BMI (kg/m2), median (IQR) 21.9 (19.7–24.4) 20.7 (17.9–23.2) 22.1 (19.9–24.6) 0.006
SOFA score, median (IQR) 6 (4–9) 7 (4–10) 6 (4–9) 0.14
ISS, median (IQR) 23.5 (14–34) 22 (17–26) 25 (14–34) 0.94
Underlying disease, n (%)
 Chronic kidney disease 15 (3.7) 2 (4.4) 13 (3.6) 0.68
 Dialysis 8 (2) 2 (4.4) 6 (1.6) 0.22
 Liver cirrhosis or failure 24 (5.8) 2 (4.4) 22 (6.0) 0.48
 Malignancies 28 (6.9) 1 (2.2) 27 (7.5) 0.35
 Immunosuppressive state 6 (1.5) 2 (4.4) 4 (1.1) 0.13
 Diabetes mellitus 101 (24.6) 13 (28.3) 88 (24.1) 0.59
Disease group, n (%)
 Cardiovascular 19 (4.6) 11 (23.9) 8 (2.2)
 Pulmonary 60 (14.6) 10 (21.7) 50 (13.7)
 Gastrointestinal and liver 77 (18.7) 2 (4.4) 75 (20.6)
 Neurogenic 21 (5.1) 1 (2.2) 20 (5.5)
 Sepsis (unknown origin or urinary tract infection) 15 (3.7) 2 (4.4) 13 (3.6)
 Trauma 170 (41.4) 14 (30.4) 156 (42.7)
 Metabolic 25 (6.1) 5 (10.9) 20 (5.5)
 Hematology 1 (0.2) 0 (0) 1 (0.3)
 Urinary 8 (2) 0 (0) 8 (2.2)
 Musculoskeletal 11 (2.7) 1 (2.2) 10 (2.7)
 Medical (other) 3 (0.7) 0 (0) 3 (0.8)
 Obstetrics and gynecology 1 (0.2) 0 (0) 1 (0.3) < 0.001
CPA before intubation, n (%) 16 (3.9) 14 (30.4) 2 (0.6) < 0.001
Reintubation, n (%) 26 (6.3) 6 (13) 20 (5.5) 0.06
VAP, n (%) 24 (5.8) 3 (6.5) 21 (5.8) 0.74
Delirium, n (%) 87 (23.5) 9 (24.3) 78 (23.4) 0.84
Methods and medication of intubation, n (%)
 No drug 26 (6.3) 26 (56.5)
 Analgesic + sedatives 20 (4.9) 20 (43.5)
 RSI (NMBA + analgesic + sedatives) 351 (85.4) 351 (96.2)
 NMBA 7 (1.7) 7 (1.9)
 NMBA + sedatives 7 (1.7) 7 (1.9) < 0.001
Video laryngoscopy, n (%) 386 (93.9) 37 (80.4) 349 (95.6) 0.001
Abnormal facial shape, n (%) 23 (5.8) 4 (8.7) 19 (5.4) 0.32
Airway obstruction, n (%) 8 (2.0) 5 (10.9) 3 (0.8) 0.001
Neck mobility limitation, n (%) 115 (28.4) 13 (28.9) 102 (28.3) 1.00
Opening mouth limitation, n (%) 92 (25.9) 12 (31.6) 80 (25.2) 0.43
GCS before intubation, median (IQR) 13 (7–15) 3.5 (3–13) 13 (9–15) < 0.001
Cormack–Lehane grade, n (%)
 1 290 (72) 25 (55.6) 265 (74)
 2 93 (23.1) 14 (31.1) 79 (22.1)
 3 18 (4.5) 5 (11.1) 13 (3.6)
 4 2 (0.5) 1 (2.2) 1 (0.3) 0.01
Specialty of the intubator, n (%)
 Resident (PGY 1, 2) 72 (17.5) 5 (10.9) 67 (18.4)
 EM resident (PGY 3–5) 201 (48.9) 22 (47.8) 179 (49.0)
 EM fellow or attendinga 130 (31.6) 19 (41.3) 111 (30.4)
 Anesthesiologist 2 (0.5) 0 (0) 2 (0.6)
 Pediatrician 6 (1.5) 0 (0) 6 (1.6) 0.53
Multiple attempts, n (%) 56 (13.6) 12 (26.1) 44 (12.1) 0.02

IQR interquartile range, SD standard deviation, NMBA neuromuscular blocking agent, ICU intensive care unit, HP hospital, BMI body mass index, SOFA score Sequential Organ Failure Assessment Score, ISS Injury Severity Score, CPA cardiopulmonary arrest, VAP ventilator associated pneumonia, ARDS acute respiratory distress syndrome, RSI rapid sequence induction, GCS Glasgow Coma Scale, PGY post graduate year, EM emergency medicine

aEM attending included intensivist